Gunjan Y. Gandhi, MD, MSc; Gregory A. Nuttall, MD; Martin D. Abel, MD; Charles J. Mullany, MD; Hartzell V. Schaff, MD; Peter C. O'Brien, PhD; Matthew G. Johnson, MPH; Arthur R. Williams, PhD; Susanne M. Cutshall, RN; Lisa M. Mundy, RN; Robert A. Rizza, MD; M. Molly McMahon, MD
ClinicalTrials.gov registration number: NCT00282698.
Acknowledgments: The authors thank Nicole Henderson, Laurie Olsen, and Lisa Schrader for recruitment of study participants, data collection and entry, and project management; Victor Montori, MD, MSc, for providing methodological expertise; and Darrell Schroeder, MS, for statistical support.
Potential Financial Conflicts of Interest:Consultancies: R.A. Rizza (Abbott, Takeda, Symphony Capital, Eli Lilly Inc.), M.M. McMahon (Baxter Healthcare); Honoraria: R.A. Rizza (Merck & Co. Inc., Novo Nordisk, Takeda, Mankind, Eli Lilly Inc.); Stock ownership or options (other than mutual funds): R.A. Rizza (Diobex); Grants received: H.V. Schaff (AstraZeneca, Atricure Inc., Avant Immunotherapeutics Inc., Baxter, Boston Scientific, Cryolife Inc., Edwards Lifesciences, Jarvik Heart Inc., Medtronic Inc., Sorin Group/Carbomedics, St. Jude Medical, Thoratec Corporation, TransTech Pharma Inc., W.L. Gore and Associates Inc.).
Requests for Single Reprints: Gunjan Y. Gandhi, MD, MSc, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Gandhi, Nuttall, Abel, Mullany, Schaff, O'Brien, Williams, Rizza, and McMahon; Mr. Johnson, Ms. Cutshall, and Ms. Mundy: Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905.
Author Contributions: Conception and design: G.Y. Gandhi, G.A. Nuttall, M.D. Abel, P.C. O'Brien, A.R. Williams, S.M. Cutshall, L.M. Mundy, R.A. Rizza, M.M. McMahon.
Analysis and interpretation of the data: G.Y. Gandhi, G.A. Nuttall, P.C. O'Brien, R.A. Rizza, M.M. McMahon.
Drafting of the article: G.Y. Gandhi, R.A. Rizza, M.M. McMahon.
Critical revision of the article for important intellectual content: G.Y. Gandhi, G.A. Nuttall, M.D. Abel, C.J. Mullany, P.C. O'Brien, A.R. Williams, R.A. Rizza, M.M. McMahon.
Final approval of the article: G.Y. Gandhi, R.A. Rizza, M.M. McMahon.
Provision of study materials or patients: C.J. Mullany, H.V. Schaff.
Statistical expertise: P.C. O'Brien, M.G. Johnson.
Obtaining of funding: A.R. Williams, R.A. Rizza, M.M. McMahon.
Administrative, technical, or logistic support: G.A. Nuttall, M.D. Abel, C.J. Mullany, H.V. Schaff, S.M. Cutshall, L.M. Mundy.
Collection and assembly of data: G.Y. Gandhi.
Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, et al. Intensive Intraoperative Insulin Therapy versus Conventional Glucose Management during Cardiac Surgery: A Randomized Trial. Ann Intern Med. 2007;146:233-243. doi: 10.7326/0003-4819-146-4-200702200-00002
Download citation file:
Published: Ann Intern Med. 2007;146(4):233-243.
Hyperglycemia occurs frequently in patients with and without diabetes during cardiac surgery, especially during cardiopulmonary bypass surgery (1, 2). In a study by Van den Berghe and colleagues (3), intensive insulin therapy after surgery reduced morbidity and death in critically ill patients, most of whom underwent cardiac surgery. As a result, professional organizations have recommended rigorous glycemic control in hospitalized patients (4) and strict glycemic control is now routine practice during the postoperative period in cardiac surgical patients.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Diabetes, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only